John P Prybylski Selected Research

gadoversetamide (OptiMARK)

1/2019

Influence of excess ligand on Nephrogenic Systemic Fibrosis associated with nonionic, linear gadolinium-based contrast agents.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John P Prybylski Research Topics

Disease

2	Nephrogenic Fibrosing Dermopathy 01/2019 - 01/2017
1	Infections 01/2017
1	Bacteremia 10/2015

Drug/Important Bio-Agent (IBA)

2	Contrast MediaIBA 01/2019 - 01/2017
2	GadoliniumIBA 01/2019 - 01/2017
2	Vancomycin FDA LinkGeneric 01/2017 - 10/2015
1	gadodiamide (Omniscan)FDA Link 01/2019
1	gadoversetamide (OptiMARK)FDA Link 01/2019
1	LigandsIBA 01/2019